Association of common genetic alterations with tumor recurrence in papillary thyroid cancer
Adding genetic testing to thyroid cancer risk assessment catches high-risk patients missed by standard classification, improving personalized management decisions.
In 2,056 PTC patients across 3 centers, RET fusions confer dramatically elevated recurrence risk (HR up to 14x) even in patients classified as low-risk by the 2025 ATA system, while BRAF V600E alone does not independently predict recurrence. Adding molecular profiling to the new ATA stratification framework directly improves precision risk stratification for PTC management.
What the study was
- Study design
- Multicenter retrospective cohort study (3 centers, 2020–2024)
- Population
- PTC patients, 3 Chinese medical centers
- Sample size
- 2056
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of the National Cancer Institute
Why it surfaced
Large n=2,056; JNCI; directly improves 2025 ATA risk stratification for PTC by adding RET fusion status — near-term clinical implementation path.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.